主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LIXT
#3813
Lixte Biotechnology Holdings, Inc. Common Stock
2.9
0
-2.68%
版块:
基础:
利润货币:
日范围
年范围
日变化
-2.68%
每月变动
-15.20%
6个月变化
-15.20%
年变化
+110.14%
前一天收盘价
2.9
8
Open
2.8
9
Bid
Ask
Low
2.8
5
High
2.9
4
交易量
20
市场
股票
医疗保健
LIXT
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.35 M
1.37 M
1.67 M
2.25 M
2.68 M
—
Valuation ratios
Enterprise value
—
—
—
4.45 M
7.91 M
45.66 M
Price to earnings ratio
—
—
—
-0.86
-1.28
-7.08
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
-1.02
-1.44
-9.3
Price to book ratio
—
—
—
8.87
-1.71
-5.68
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.62
-1.32
-1.14
-1.18
-3.13
-2.02
Return on equity %
0.65
-1.4
-1.22
-1.27
-4.33
-2.95
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.15
16.81
14.08
13.73
3.6
17.65
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-2.92
-2.24
-1.41
-0.93
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
3.38
2.19
0.46
1.77
Net current asset value per share
—
—
3.51
2.25
0.51
2.58
Tangible book value per share
—
—
1.05
0.26
-1.19
-1.26
Working capital per share
—
—
3.26
2.09
0.37
1.95
Book value per share
—
—
1.05
0.26
-1.19
-1.26
新闻
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary
LIXTE expands clinical trial for ovarian cancer treatment
Lixte生物科技在430万美元直接发行后股价下跌
斯巴达资本担任Lixte 430万美元融资的配售代理
Lixte Biotechnology stock falls after $4.3 million direct offering
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering
Lixte生物科技股价在430万美元直接融资后下跌
Lixte Biotechnology stock falls after $4.3 million direct offering
Lixte Biotechnology raises $4.3 million in registered direct offering
Lixte生物科技股东批准董事会提名人选和股票计划修订案
Lixte Biotechnology shareholders approve board nominees and stock plan amendment
Lixte生物科技股价在收购英国Liora后下跌